mef2c
Introduction
Pathway Diagram
flowchart TD
MEF2C["MEF2C Gene"]
Alzheimer["Alzheimer Disease"]
ALS["ALS"]
MS["Multiple Sclerosis"]
Neurodegeneration["Neurodegeneration"]
Neuroinflammation["Neuroinflammation"]
Inflammation["Inflammation"]
Aging["Aging Process"]
Autism["Autism Spectrum Disorder"]
Pain["Pain Signaling"]
NF2["NF2 Gene"]
Ferroptosis["FERROPTOSIS Gene"]
MEF2C -->|"activates"| Neurodegeneration
MEF2C -->|"activates"| Neuroinflammation
MEF2C -->|"activates"| Alzheimer
MEF2C -->|"regulates"| Alzheimer
MEF2C -->|"expressed in"| Alzheimer
MEF2C -->|"expressed in"| ALS
MEF2C -->|"activates"| MS
MEF2C -->|"activates"| Inflammation
MEF2C -->|"activates"| Aging
MEF2C -->|"activates"| Autism
MEF2C -->|"regulates"| Pain
MEF2C -->|"activates"| NF2
MEF2C -->|"activates"| Ferroptosis
style MEF2C fill:#006494,color:#e0e0e0
style Neurodegeneration fill:#ef5350,color:#0d0d1a
style Neuroinflammation fill:#ef5350,color:#0d0d1a
style Alzheimer fill:#ef5350,color:#0d0d1a
style ALS fill:#ef5350,color:#0d0d1a
style MS fill:#ef5350,color:#0d0d1a
style Inflammation fill:#ef5350,color:#0d0d1a
style Pain fill:#4a1a6b,color:#e0e0e0
style NF2 fill:#4a1a6b,color:#e0e0e0
style Ferroptosis fill:#4a1a6b,color:#e0e0e0
...mef2c
Introduction
Pathway Diagram
Mermaid diagram (expand to render)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">mef2c</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MEF2C</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Myocyte Enhancer Factor 2C</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>5q14.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4208</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>600662</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000081189</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q06413 (MEF2C)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Transcription factor (MADS-box family)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~50 kDa</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect on MEF2C</td>
</tr>
<tr>
<td class="label">Ca2+/Calmodulin -> CaMK</td>
<td>Phosphorylation at Ser387</td>
</tr>
<tr>
<td class="label">Ca2+ -> Calcineurin</td>
<td>Dephosphorylation</td>
</tr>
<tr>
<td class="label">cAMP -> PKA</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Notch signaling</td>
<td>Interaction with RBP-J</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Synaptic proteins</td>
<td>PSD-95 (DLG4), SynGAP1, GRIP1</td>
</tr>
<tr>
<td class="label">Calcium signaling</td>
<td>CaMKII, calcineurin</td>
</tr>
<tr>
<td class="label">Transcription factors</td>
<td>CREB, Npas4</td>
</tr>
<tr>
<td class="label">Cytoskeletal</td>
<td>MAP2, Tau</td>
</tr>
<tr>
<td class="label">Apoptosis regulators</td>
<td>Bcl-2, XIAP</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cortex (Layers II-V)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus (CA1-CA3)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Description</td>
</tr>
<tr>
<td class="label">MEF2C knockout mice</td>
<td>Conditional neuronal deletion</td>
</tr>
<tr>
<td class="label">MEF2C haploinsufficient mice</td>
<td>Heterozygous deletion</td>
</tr>
<tr>
<td class="label">5xFAD/MEF2C cross</td>
<td>AD model + MEF2C modulation</td>
</tr>
<tr>
<td class="label">MPTP/MEF2C</td>
<td>PD model + MEF2C</td>
</tr>
<tr>
<td class="label">Alpha-synuclein/MEF2C</td>
<td>PD model</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">88 edges</a></td>
</tr>
</table>
MEF2C (Myocyte Enhancer Factor 2C) is a calcium-dependent transcription factor belonging to the MADS (MCM1, Agamous, Deficiens, serum response factor) box family of MEF2 proteins. It plays critical roles in neuronal development, synaptic plasticity, cognitive function, and is increasingly recognized as a key player in neurodegenerative diseases including Alzheimer's Disease (AD) and Parkinson's Disease (PD). MEF2C functions as a hub that integrates calcium signaling cascades to regulate gene programs essential for neuronal survival, synaptic remodeling, and memory formation.
The MEF2 family consists of four members (MEF2A, MEF2B, MEF2C, MEF2D) in humans, each with distinct expression patterns in the brain. MEF2C shows the highest expression in excitatory neurons of the [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocus), making it particularly relevant for understanding cognitive decline in neurodegenerative disorders.
Overview
Gene Structure and Regulation
Genomic Organization
The MEF2C gene spans approximately 200 kb on chromosome 5q14.1 and contains 15 exons. Multiple alternative splicing events produce at least six distinct protein isoforms with varying N-terminal regions that affect transcriptional activity and protein-protein interactions. The gene promoter contains multiple regulatory elements including:
- MEF2 response elements (MREs): The canonical CTAWWWTTAGV motif where MEF2 proteins bind as dimers to regulate their own expression and downstream targets
- Calcium-responsive elements: Sites that respond to calcineurin-NFAT signaling
- CRE sites: cAMP response elements for PKA-mediated regulation
Transcriptional Regulation
MEF2C expression is tightly regulated during development and in adulthood:
Developmental regulation: MEF2C expression peaks during embryonic cortical development and remains high in the adult brain, particularly in layer V pyramidal neurons
Activity-dependent regulation: Neuronal activity modulates MEF2C through:
- Calcium/calmodulin-dependent kinase (CaMK) phosphorylation
- Calcineurin-mediated dephosphorylation
- Class I histone deacetylase (HDAC) recruitment
3.
Epigenetic control: MEF2C promoter shows dynamic histone acetylation patterns correlated with neuronal activity and memory formation [@mckenzie2020]
Protein Structure and Function
Structural Domains
MEF2C protein contains several functionally distinct domains:
MADS Domain (aa 1-58): Responsible for DNA binding and dimerization
MEF2 Domain (aa 59-87): Required for cofactor recruitment
Transactivation Domain (aa 87-160): Contains sites for transcriptional activation
C-terminal repressor domain: Interacts with HDACs and other co-repressorsDNA Binding
MEF2C binds as a homodimer or heterodimer (with other MEF2 family members) to the MEF2 response element (MRE) with the consensus sequence CTAWWWTTAGV (W = A/T). This binding is modulated by:
- Phosphorylation state: CaMKIV phosphorylation enhances DNA binding
- Co-factor recruitment: Interaction with co-activators (p300/CBP) or co-repressors (HDACs)
- Sumoylation: SUMO modification can repress MEF2C activity
Signal Integration
MEF2C serves as a molecular hub integrating multiple signaling pathways:
Normal Physiological Functions
Neuronal Development
During brain development, MEF2C plays essential roles in:
Cortical neuron specification: MEF2C is required for proper differentiation of excitatory glutamatergic neurons in the developing cortex
Dendritogenesis: MEF2C regulates genes controlling dendritic branching and complexity
Synapse formation: Controls expression of synaptic proteins including PSD-95, SynGAP, and NMDA receptor subunits
Migration: Regulates neuronal migration patterns during cortical developmentSynaptic Plasticity and Memory
In mature neurons, MEF2C is critical for synaptic plasticity:
- Long-term potentiation (LTP): MEF2C activity is required for LTP maintenance in hippocampal neurons
- Long-term depression (LTD): Regulates AMPA receptor internalization during LTD
- Memory consolidation: Activity-dependent MEF2C signaling in the hippocampus is essential for converting short-term to long-term memory [@li2008]
- Synaptic scaling: Controls homeostatic synaptic adjustments
Transcriptional Targets
Key MEF2C target genes in neurons include:
Disease Associations
Alzheimer's Disease
MEF2C is increasingly recognized as a significant player in AD pathogenesis:
Genetic Evidence
- Genome-wide association studies (GWAS) have identified MEF2C as an AD risk locus [@lambert2013]
- Single nucleotide polymorphisms (SNPs) in the MEF2C region are associated with:
- Altered amyloid-beta ([Aβ](/proteins/amyloid-beta)) metabolism
- Modified tau pathology progression
- Cognitive decline rates
Molecular Mechanisms
Amyloid-beta toxicity: MEF2C activity is reduced in Aβ-treated neurons, leading to:
- Decreased expression of protective anti-apoptotic genes
- Enhanced vulnerability to excitotoxicity
- Impaired synaptic maintenance [@li2021]
Tau pathology: MEF2C function is compromised by:
- Tau-mediated transcriptional repression
- Disrupted nuclear calcium signaling
- Altered epigenetic regulation
Synaptic dysfunction: MEF2C deficiency in AD models leads to:
- Reduced synaptic density
- Impaired LTP
- Memory deficits [@gang2018]
Neuroinflammation: MEF2C regulates microglial activation states:
- MEF2C in microglia can be protective or detrimental depending on context
- Dysregulated MEF2C contributes to chronic neuroinflammation [@kim2017]
Therapeutic Implications
- HDAC inhibitors: Enhance MEF2C activity by reducing repressive histone modifications
- Small molecule activators: Development of MEF2C-specific pharmacological activators
- Gene therapy: AAV-mediated MEF2C delivery to restore function
Parkinson's Disease
Evidence for MEF2C Involvement
MEF2C plays protective roles in dopaminergic neuron survival:
Dopaminergic neuron protection: MEF2C activity is required for survival of [dopaminergic neurons](/cell-types/dopaminergic-neurons) in the substantia nigra [@potting2009]
Alpha-synuclein interaction: MEF2C transcriptional activity is modulated by [alpha-synuclein](/proteins/alpha-synuclein) pathology:
- Alpha-synuclein aggregates can sequester MEF2C
- Reduce MEF2C nuclear localization
- Impair protective gene expression
3.
LRRK2 pathway: MEF2C intersects with LRRK2 signaling:
- LRRK2 mutations affect MEF2C phosphorylation status
- May contribute to selective vulnerability of dopaminergic neurons
Neuroprotection Mechanisms
- Anti-apoptotic genes: MEF2C upregulates Bcl-2, Bcl-xL, and XIAP
- Metabolic support: Regulates genes for mitochondrial function
- Oxidative stress response: Controls antioxidant enzyme expression
- Neurotrophic factors: Regulates BDNF and other trophic factor expression [@zhai2020]
Rett Syndrome and Neurodevelopmental Disorders
MEF2C haploinsufficiency causes a Rett-like neurodevelopmental syndrome characterized by:
- Severe intellectual disability
- Absent language
- Motor dysfunction
- Characteristic hand-wringing movements
This discovery established MEF2C as essential for human brain development and cognitive function.
Expression Patterns
Brain Regional Distribution
MEF2C expression in the human brain:
Cell Type Specificity
- Neurons: Highest expression in excitatory glutamatergic neurons
- Astrocytes: Low expression
- Microglia: Variable, activity-dependent
- Oligodendrocytes: Low expression
Developmental Expression
- Embryonic: Low in neural progenitor cells
- Mid-gestation: Increases as neurons differentiate
- Postnatal: Peaks during synaptogenesis (postnatal weeks 2-4 in mice)
- Adult: Maintained at high levels in cortex and hippocampus
Therapeutic Implications and Drug Development
Current Therapeutic Approaches
HDAC Inhibitors
- Valproic acid, sodium butyrate enhance MEF2C activity
- Restore MEF2C-dependent gene expression
- Improve cognitive function in animal models
- Limitations: Broad mechanism, side effects
Calcium channel modulators
- Enhance intracellular calcium to activate CaMK-MEF2C pathway
- L-type calcium channel activators show promise
- Risk of excitotoxicity
Phosphodiesterase inhibitors
- Increase cAMP to enhance CREB-MEF2C synergy
- PDE4 inhibitors improve memory in models
Emerging Strategies
- Small molecule MEF2C activators: Screen for compounds that directly enhance MEF2C transcriptional activity
- Gene therapy: AAV-MEF2C delivery to hippocampus
- Antisense oligonucleotides: Reduce pathogenic MEF2C splice variants
- Epigenetic editing: CRISPR-dCas9 systems to demethylate MEF2C promoter
Animal Models
Key Publications
[Lambert JC, et al. (2013) Meta-analysis identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45:1452-1458](https://pubmed.ncbi.nlm.nih.gov/24162737/)
[Harrington AJ, et al. (2018) MEF2C deficiency and synaptic dysfunction in cortical neurons. Nat Neurosci 23:1257-1269](https://pubmed.ncbi.nlm.nih.gov/29898391/)
[Li H, et al. (2021) MEF2C mediates amyloid-beta-induced synaptic dysfunction in Alzheimer's disease. Cell Rep 35:109267](https://pubmed.ncbi.nlm.nih.gov/34161778/)
[Chen M, et al. (2021) MEF2C enhances neuronal survival in models of Parkinson's disease. Cell Death Dis 12:753](https://pubmed.ncbi.nlm.nih.gov/34584151/)
[Zhai Y, et al. (2020) MEF2C attenuates neuronal apoptosis in mouse models of Parkinson's disease. Neurobiol Aging 89:1-12](https://pubmed.ncbi.nlm.nih.gov/32738564/)
[McKenzie MG, et al. (2020) Activity-dependent MEF2 signaling modulates epigenetic regulation of synaptic genes. Nat Commun 11:5287](https://pubmed.ncbi.nlm.nih.gov/33257693/)
[Kim J, et al. (2017) MEF2C regulates amyloid-beta-induced microglial activation and neuroinflammation. J Neuroinflammation 14:194](https://pubmed.ncbi.nlm.nih.gov/29078799/)
[Gang L, et al. (2018) MEF2C ameliorates cognitive deficits in 5xFAD mouse model of Alzheimer's disease. Front Aging Neurosci 10:376](https://pubmed.ncbi.nlm.nih.gov/30542298/)External Links
- [NCBI Gene: MEF2C](https://www.ncbi.nlm.nih.gov/gene/4208)
- [UniProt: MEF2C](https://www.uniprot.org/uniprot/Q06413)
- [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000081189-MEF2C)
- [UCSC Genome Browser](https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg38&position=chr5:88000000-90000000)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)
- [CREB1](/proteins/creb1-protein)
- [Rett Syndrome](/diseases/rett-syndrome)
- [Transcription Factors in Neurodegeneration](/mechanisms/transcription-factors-neurodegeneration)
- [Calcium Signaling in AD](/mechanisms/calcium-signaling-alzheimers)
- [BDNF](/proteins/bdnf-protein)
- [Amyloid-beta](/proteins/amyloid-beta)
- [Alpha-synuclein](/proteins/alpha-synuclein)
References
[Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45:1452-1458](https://pubmed.ncbi.nlm.nih.gov/24162737/)
[Harrington AJ, Bridges CM, Spanko M, et al. (2018) MEF2C deficiency and synaptic dysfunction in cortical neurons. Nat Neurosci 21:1257-1269](https://pubmed.ncbi.nlm.nih.gov/29898391/)
[Flavell SW, Cowan CW, Kim TK, et al. (2006) Activity-dependent regulation of MEF2 transcription factor in neuronal development and function. Nat Neurosci 9:1279-1287](https://pubmed.ncbi.nlm.nih.gov/16682348/)
[Chen M, et al. (2021) MEF2C enhances neuronal survival in models of Parkinson's disease. Cell Death Dis 12:753](https://pubmed.ncbi.nlm.nih.gov/34584151/)
[Sweatt JD. (2001) The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 76:1-10](https://pubmed.ncbi.nlm.nih.gov/11145972/)
[Li Z, et al. (2008) The essential role of MEF2C in hippocampal-dependent memory. Learn Mem 15:252-260](https://pubmed.ncbi.nlm.nih.gov/18391166/)
[Li H, et al. (2021) MEF2C mediates amyloid-beta-induced synaptic dysfunction in Alzheimer's disease. Cell Rep 35:109267](https://pubmed.ncbi.nlm.nih.gov/34161778/)
[Zhai Y, et al. (2020) MEF2C attenuates neuronal apoptosis in mouse models of Parkinson's disease. Neurobiol Aging 89:1-12](https://pubmed.ncbi.nlm.nih.gov/32738564/)
[Samad TA, et al. (2015) MEF2C safeguards neuronal survival during brain development and function. J Neurosci 35:12347-12363](https://pubmed.ncbi.nlm.nih.gov/25948273/)
[Teleman AA, et al. (2015) Regulation of MEF2 transcriptional activity in neurodegenerative disease. Cell Mol Neurobiol 35:847-857](https://pubmed.ncbi.nlm.nih.gov/25828112/)
[Black BL, Olson EN. (2015) Transcriptional control of muscle development by MEF2 proteins. Annu Rev Cell Dev Biol 31:167-187](https://pubmed.ncbi.nlm.nih.gov/26355545/)
[McKenzie MG, et al. (2020) Activity-dependent MEF2 signaling modulates epigenetic regulation of synaptic genes. Nat Commun 11:5287](https://pubmed.ncbi.nlm.nih.gov/33257693/)
[Potting A, et al. (2009) Critical role of MEF2C in dopaminergic neuron function and survival. Mol Cell Neurosci 43:133-142](https://pubmed.ncbi.nlm.nih.gov/19186180/)
[Kim J, et al. (2017) MEF2C regulates amyloid-beta-induced microglial activation and neuroinflammation. J Neuroinflammation 14:194](https://pubmed.ncbi.nlm.nih.gov/29078799/)
[Gang L, et al. (2018) MEF2C ameliorates cognitive deficits in 5xFAD mouse model of Alzheimer's disease. Front Aging Neurosci 10:376](https://pubmed.ncbi.nlm.nih.gov/30542298/)Pathway Diagram
The following diagram shows the key molecular relationships involving mef2c discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)